Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • URB597 (KDS-4103): Selective FAAH Inhibition for Neuroscienc

    2026-05-06

    URB597 (KDS-4103): Selective FAAH Inhibition for Neuroscience

    Executive Summary: URB597 (KDS-4103) is a potent, selective inhibitor of fatty acid amide hydrolase (FAAH), effectively blocking enzymatic degradation of the endocannabinoid anandamide at nanomolar concentrations (IC50: 4.6 nM in brain membranes) (product_spec). It shows minimal off-target activity, making it a preferred tool in endocannabinoid pathway studies (workflow_recommendation). URB597 enhances anandamide and other fatty acid ethanolamide levels in vivo, with effects persisting over 12 hours post-intraperitoneal rat administration (product_spec). Unlike direct cannabinoid agonists, URB597 does not alter core body temperature when administered alone, but it potentiates anandamide's hypothermic effects (workflow_recommendation). APExBIO supplies URB597 (SKU A4372) with validated solubility and storage guidelines, supporting reproducible neuroscience protocols (product_spec).

    Biological Rationale

    The endocannabinoid system modulates pain, mood, and neuroinflammation through endogenous ligands such as anandamide. FAAH is the primary enzyme hydrolyzing anandamide, tightly regulating its signaling tone. Inhibition of FAAH by agents like URB597 leads to elevated anandamide concentrations, amplifying endocannabinoid signaling without directly activating cannabinoid receptors (product_spec). This mechanism is relevant for conditions where altered endocannabinoid tone is implicated, including pain, depression, and neuroinflammatory disorders (CBD-bridge).

    Mechanism of Action of URB597

    URB597 is a carbamate-based, irreversible FAAH inhibitor. It covalently modifies the active-site serine of FAAH, leading to persistent blockade of enzymatic activity. In brain tissue membranes, URB597 demonstrates an IC50 of 4.6 nM; in intact neurons, the IC50 is 0.5 nM (product_spec). The compound does not interact with cannabinoid receptors (CB1/CB2), anandamide transporters, or unrelated ion channels and enzymes, ensuring high pathway specificity (workflow_recommendation). This selectivity permits precise modulation of endocannabinoid signaling in experimental settings.

    Evidence & Benchmarks

    • URB597 inhibits rat brain FAAH with IC50 = 4.6 nM in membrane assays (product_spec).
    • In intact neurons, URB597 achieves FAAH inhibition with IC50 = 0.5 nM (product_spec).
    • Intraperitoneal administration in rats (dose range: 0.3–1 mg/kg) inhibits brain FAAH activity within 15 minutes, with effects lasting >12 hours (product_spec).
    • URB597 administration elevates anandamide and N-acylethanolamine levels in the brain, with minimal direct action on CB1/CB2 receptors (workflow_recommendation).
    • No significant off-target effects on anandamide transporters, unrelated enzymes, or ion channels detected at experimental concentrations (product_spec).
    • Does not induce hypothermia alone but enhances the hypothermic effect of exogenous anandamide in vivo (workflow_recommendation).
    • URB597 is insoluble in water but soluble up to 16.9 mg/mL in DMSO and 4.55 mg/mL in ethanol with warming and sonication (product_spec).
    • For optimal stability, URB597 should be stored at -20°C; long-term solutions are not recommended (product_spec).

    For additional practical benchmarking and assay optimization, see: URB597 (KDS-4103): Reliable FAAH Inhibition for Lab Assays (this article provides hands-on troubleshooting advice not covered here).

    Applications, Limits & Misconceptions

    URB597 is widely used for:

    • Probing endocannabinoid signaling modulation and neuroplasticity research (protocol_guide).
    • Modeling neuroinflammation and depression in rodents (product_spec).
    • Studying catecholaminergic activity and pain processing in preclinical models (workflow_recommendation).

    Unlike direct cannabinoid agonists, URB597 does not produce classical psychoactive effects. It is not a therapeutic agent but a research tool compound (product_spec).

    Recent studies on cannabidiol (CBD) demonstrate that FAAH inhibition is a critical mechanism for reducing not just sensory pain but also the affective components of chronic pain, underscoring the translational value of FAAH-targeted modulation (CBD-contrast). This article extends these insights by focusing on the specificity and laboratory utility of URB597 in controlled models.

    Common Pitfalls or Misconceptions

    • URB597 is not water-soluble and must be dissolved in DMSO or ethanol for biological assays (workflow_recommendation).
    • It does not directly activate cannabinoid receptors; all effects are mediated via endocannabinoid accumulation (product_spec).
    • Prolonged storage of URB597 in solution can reduce potency (workflow_recommendation).
    • Behavioral effects are context-dependent and do not mimic THC or pure cannabinoid agonists (protocol_guide).
    • Off-target enzyme or transporter inhibition is negligible at recommended working concentrations (product_spec).

    Workflow Integration & Parameters

    Protocol Parameters

    • FAAH inhibition (brain membranes) | IC50 4.6 nM | enzyme assays, rat brain | Benchmark for inhibitor potency | product_spec
    • FAAH inhibition (intact neurons) | IC50 0.5 nM | cultured neuron models | Highest sensitivity detection | product_spec
    • Solubility | ≥16.9 mg/mL in DMSO, ≥4.55 mg/mL in ethanol | compound preparation | Ensures complete dissolution; avoid water | product_spec
    • Storage | -20°C (solid), avoid long-term solutions | all applications | Maintains compound integrity | product_spec
    • In vivo administration | 0.3–1 mg/kg i.p. in rats | rodent behavioral assays | Rapid, sustained FAAH inhibition | product_spec
    • Workflow suggestion: Prepare fresh solutions before each use; verify solubility visually (workflow_recommendation).

    For protocol troubleshooting and advanced data interpretation, see: URB597 (KDS-4103): Reliable FAAH Inhibition for Endocannabinoid Studies (contrasting this article's focus on selectivity and in vivo benchmarks).

    Conclusion & Outlook

    URB597 (KDS-4103) remains a reference standard for selective FAAH inhibition in preclinical neuroscience and pain research. Its robust selectivity, rapid onset, and long duration of in vivo effect facilitate reproducible studies of endocannabinoid function. Future research is likely to further elucidate the distinct contributions of FAAH inhibition to neuroplasticity, pain modulation, and emotional behavior, as highlighted by recent work on CBD and endocannabinoid pathways (CBD-mechanism). For product details, validated protocols, and batch-specific data, refer to the APExBIO URB597 (SKU A4372) page.